Oxford Biomedica Share Price, News & Analysis (LON:OXB) GBX 198.40 +16.20 (+8.89%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range 180.73▼ 200.5050-Day Range 166.60▼ 307.5052-Week Range 164.29▼ 575Volume628,402 shsAverage Volume175,346 shsMarket Capitalization£192.01 millionP/E RatioN/ADividend Yield4.57%Price TargetGBX 605 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Oxford Biomedica MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside204.9% UpsideGBX 605 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.60Based on 3 Articles This WeekInsider TradingAcquiring Shares£12.12 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 stars 3.2 Analyst's Opinion Consensus RatingOxford Biomedica has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 605, Oxford Biomedica has a forecasted upside of 204.9% from its current price of GBX 198.40.Amount of Analyst CoverageOxford Biomedica has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for OXB. Previous Next 1.7 Dividend Strength Dividend LeadershipOxford Biomedica is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthOxford Biomedica does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OXB. Previous Next 2.0 News and Social Media Coverage News SentimentOxford Biomedica has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Oxford Biomedica this week, compared to 0 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oxford Biomedica insiders have bought more of their company's stock than they have sold. Specifically, they have bought £121,206.20 in company stock and sold GBX 0 in company stock.Percentage Held by InsidersOnly 8.68% of the stock of Oxford Biomedica is held by insiders.Percentage Held by Institutions67.05% of the stock of Oxford Biomedica is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Oxford Biomedica is -310.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oxford Biomedica is -310.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOxford Biomedica has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Oxford Biomedica Stock (LON:OXB)Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.Read More OXB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OXB Stock News HeadlinesDecember 5, 2023 | americanbankingnews.comOxford Biomedica (LON:OXB) Shares Pass Below Two Hundred Day Moving Average of $335.58December 4, 2023 | msn.comOxford Biomedica inks deal to provide ‘footprint’ in EU marketDecember 9, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.December 4, 2023 | finance.yahoo.comOxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMOOctober 22, 2023 | finance.yahoo.comOxford Biomedica's UK£39m Market Cap Fall Books Insider LossesSeptember 22, 2023 | finance.yahoo.comOxford Biomedica First Half 2023 Earnings: Misses ExpectationsSeptember 20, 2023 | finance.yahoo.comOxford BioMedica shares soar as vaccine maker raises earnings guidanceJuly 18, 2023 | finance.yahoo.comOxford Biomedica Implements Sapio Sciences' Electronic Laboratory NotebookDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comMay 25, 2023 | msn.comRBC Capital Markets Reiterates Oxford Biomedica (LSE:OXB) Outperform RecommendationMay 15, 2023 | finance.yahoo.comOxford Biomedica launches TetraVecta - the next generation lentiviral vector systemMay 5, 2023 | finance.yahoo.comWhy Investors Shouldn't Be Surprised By Oxford Biomedica plc's (LON:OXB) Low P/SApril 26, 2023 | finance.yahoo.comOxford Biomedica Appoints Leone Patterson as Non-Executive DirectorApril 25, 2023 | markets.businessinsider.comOxford Biomedica Posts FY LossApril 21, 2023 | marketwatch.com2023-2030 "CGT CDMO Market" Share | Global Industry Analysis and ForecastApril 12, 2023 | marketwatch.com2023-2030 Global CGT CDMO Market is Growing Rapidly with Modern TrendMarch 26, 2023 | marketwatch.comCGT CDMO Market Share and Forecast till 2030March 15, 2023 | benzinga.comOxford BioMedica Stock (OTC:OXBDF), Quotes and News SummaryMarch 11, 2023 | finance.yahoo.comAs Oxford Biomedica plc's market cap (LON:OXB) drops to UK£484m, insiders might be questioning their decision to buy earlier this yearFebruary 25, 2023 | marketwatch.comWhat is a CAGR of CGT CDMO Market? CGT CDMO Market Value in 2028 with Competition Analysis Data of Top Key PlayersFebruary 22, 2023 | marketwatch.comCGT CDMO Market Size Global Research Report, 2023 - 2028January 30, 2023 | marketwatch.comCGT CDMO Market Size 2023 Trend and Opportunities, Analysis, CAGR and Value Chain Study, Business Growth to 2028January 20, 2023 | marketwatch.comCGT CDMO Market Provides an In-Depth Insight of Trends and Landscape Outlook 2023-2028January 12, 2023 | marketwatch.comCGT CDMO Market Present Development Scenario and Growth Prospects to help you understand the Implications for Your Business | Newest 112 InsightsJanuary 1, 2023 | finance.yahoo.comA Look At The Intrinsic Value Of Oxford Biomedica plc (LON:OXB)December 14, 2022 | yahoo.comOxford Biomedica Solutions forms new partnerships with three biotechnology companiesDecember 9, 2022 | marketwatch.comCGT CDMO Market 2022 : Incredible Possibilities, Growth Analysis and Forecast To 2028See More Headlines Receive OXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:OXB CUSIPN/A CIKN/A Webwww.oxfordbiomedica.co.uk Phone+44-1865-783000FaxN/AEmployees891Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 605 High Stock Price TargetGBX 1,010 Low Stock Price TargetGBX 310 Potential Upside/Downside+204.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-61,630,000.00 Net Margins-51.78% Pretax MarginN/A Return on Equity-30.64% Return on Assets-12.05% Debt Debt-to-Equity Ratio57.10 Current Ratio3.32 Quick Ratio1.67 Sales & Book Value Annual Sales£119.02 million Price / Sales1.61 Cash FlowGBX 65.99 per share Price / Cash Flow3.01 Book ValueGBX 178 per share Price / Book1.11Miscellaneous Outstanding Shares96,780,000Free FloatN/AMarket Cap£192.01 million OptionableNot Optionable Beta1.02 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Stuart Paynter (Age 50)CFO, Company Secretary & Director Comp: $832kDr. Frank Mathias (Age 61)CEO & Director Mr. Thierry CournezCOO & Site Head of UK OperationsDr. James Miskin Ph.D.Chief Technical OfficerDr. Kyriacos Mitrophanous Ph.D.Chief Scientific OfficerMr. Matthew TreagusChief Information Officer & Chief of StaffSophia BolhassanHead of Investor RelationsMs. Natalie Louise WalterGeneral CounselMs. Lisa JamesChief People OfficerMs. Kati HudsonHead of Intellectual Property and ContractsMore ExecutivesKey CompetitorsFaron Pharmaceuticals OyLON:FARNArix BioscienceLON:ARIXCircassia GroupLON:CIRBioventixLON:BVXPhVIVOLON:HVOView All CompetitorsInsidersMichael HaydenBought 10,000 shares on 11/13/2023Total: £1.93 M ($193.00/share)Dame Kay DaviesBought 1,000 shares on 9/26/2023Total: £291,000.00 ($291.00/share)Roch DoliveuxBought 36,130 shares on 9/20/2023Total: £9.90 M ($274.00/share)Catherine MoukheibirBought 6,684 shares on 7/3/2023Total: £2.87 M ($430.00/share)View All Insider Transactions OXB Stock Analysis - Frequently Asked Questions Should I buy or sell Oxford Biomedica stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OXB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXB, but not buy additional shares or sell existing shares. View OXB analyst ratings or view top-rated stocks. What is Oxford Biomedica's stock price target for 2024? 3 brokers have issued 1-year target prices for Oxford Biomedica's shares. Their OXB share price targets range from GBX 310 to GBX 1,010. On average, they anticipate the company's stock price to reach GBX 605 in the next year. This suggests a possible upside of 204.9% from the stock's current price. View analysts price targets for OXB or view top-rated stocks among Wall Street analysts. How have OXB shares performed in 2023? Oxford Biomedica's stock was trading at GBX 442.50 on January 1st, 2023. Since then, OXB stock has decreased by 55.2% and is now trading at GBX 198.40. View the best growth stocks for 2023 here. What other stocks do shareholders of Oxford Biomedica own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL). How do I buy shares of Oxford Biomedica? Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:OXB) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.